Você procurou por: valuea (Inglês - Alemão)

valuea
werta

p valuea
p- werta

p-valuea
n=268

p-valuea, b
p-werta, b

or; 95% ci; p valuea
or; 95% ci; p-

p-valuea (2-sided)
p-werta (2-seitig)

or enter an absolute valuea for a goto (alt pf3)
oder eine absolute adresse in goto (alt pf3)

95% ci for hazard ratio (0.4316 to 0.6430) p-valuea <0.0001
95%-ki für die hazard ratio (0,4316 bis 0,6430) p-werta < 0,0001

n = 391 n = 195 p-valuea 1.21 2.32 0.012 0.63 1.14 0.029 0.58 1.18 0.009
n = 391 n = 195 p-werta 1,21 2,32 0,012 0,63 1,14 0,029

ribavirin ribavirin p (800- (800- (800 mg) (800 mg) valuea 1,200 mg) d
(1,5 µg/kg/ (3 mio i.e. µg/woche) + tiw) woche) + tiw) + ribavirin +ribavirin ribavirin ribavirin p- (800- (800- (800 mg) (800 mg) werta 1.200 mg)d 1.200 mg)d p-wertb

sustained virological response based on genotype after viraferonpeg in combination with ribavirin in hcv/hiv co-infected patients study 11 study 22 viraferonpeg interferon viraferonpeg interferon (100 or alfa-2b 150c µg/week) (3 miu tiw) (1.5 µg/kg/alfa-2b week) + (3 miu tiw) + + ribavirin + ribavirin p ribavirin ribavirin (800-(800-p valueb 1,200 mg)d 1,200 mg)d valuea (800 mg) (800 mg) 27% (56/205) 20% (41/205) 0.047 44% (23/52) 21% (9/43) 0.017 17% (21/125) 6% (8/129) 0.006 38% (12/32) 7% (2/27) 0.007 44% (35/80) 43% (33/76) 0.88 53% (10/19) 47% (7/15)
anhaltendes virologisches ansprechen basierend auf dem genotyp nach viraferonpeg in kombination mit ribavirin bei hcv/hiv co-infizierten patienten studie 11 studie 22 viraferonpeg interferon interferon (100 oder alfa-2b 150c viraferonpeg alfa-2b (3 mio i.e.(1,5 µg/kg/(3 mio i.e. µg/woche) + tiw) woche) + tiw) + ribavirin +ribavirin ribavirin ribavirin p-(800-(800-p-wertb werta 1.200 mg)d 1.200 mg)d (800 mg) (800 mg) 27% (56/205) 20% (41/205) 0,047 44% (23/52) 21% (9/43) 0,017 17% (21/125) 6% (8/129) 0,006 38% (12/32) 7% (2/27) 0,007 44% (35/80) 43% (33/76) 0,88 53% (10/19) 47% (7/15) internationale einheiten; tiw = dreimal in der woche.